Form D · Pharmaceuticals
AngioGenex, Inc.
New York, NY · CIK 0001085596
Offering snapshot reported Dec 17, 2021 · SEC filing
- Reported sold
- $260K Offering amount: $260K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 17, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 17, 2021 | Initial | $260,000 | No comparison | 1 | SEC filing |
| Dec 3, 2009 | Initial | $25,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-425689
Source: Form D, filed Dec 17, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Aronstein | Director, Executive |
| William Garland | Director, Executive |
| Martin Murray | Director, Executive |
| Richard Salvador | Director, Executive |
| Michael Strage | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
425 Madison Avenue, Suite 902
New York, NY, 10017
New York, NY, 10017